Novo Nordisk and Eli Lilly are offering discounts to encourage more insurance coverage of the medicines, which carry price tags of over $1,000 a month.

Weight-loss drugs like Ozempic are booming in popularity, but experts warn they aren't silver bullets for obesity.

F ROM LOS ANGELES to London, weight-loss drugs such as Ozempic are reshaping culture as much as waistlines. Some Ozempic-takers have tiny appetites and dine at unusual hours to avoid spells of nausea.

Many people are doing an end-run around their doctor's office, reaching out to potentially unreliable sources that promise to set them up with Wegovy, Zepbound and other weight-loss drugs.

One of the researchers described the circumstances that led to the discovery as “serendipity.” This year’s prestigious Lasker medical awards recognize a trio of scientists without whom Ozempic and other blockbuster weight-loss drugs might not exist.

In a society that has so many people who are overweight, it is understandable there’s such a craze for new drugs that are helping people to lose weight. Drugs like Ozempic and Wegovy were developed for people with diabetes but have proven to be great resources for losing weight.